Type 2 diabetes patients given daily injections of investigational liraglutide atop oral metformin and rosiglitazone (Avandia) achieved significant reductions in plasma glucose by a drop in A1c of 1.5%, with lower blood pressures and weight loss, researchers reported.

In a month-long head-to-head trial, the incretin mimetic exenatide (Byetta) reduced postprandial glucose in type 2 diabetes more than did sitagliptin (Januvia), an oral DPP-4 inhibitor, researchers reported.

Adults with type 1 diabetes achieved significantly better A1c levels with six months of continuous monitoring than with home monitoring, researchers reported.

Adding 50 mg of sitagliptin (Januvia) to pioglitazone (Actos) allowed patients with type 2 diabetes to achieve sustained glycemic control, a yearlong trial showed.

Adolescents and young adults with type 2 diabetes are more likely to have hypertension, generalized obesity, abdominal obesity, low HDL cholesterol, high triglycerides and microalbuminuria, than their non-diabetic counterparts.

New research has shown that XOMA 52, an antibody drug can address the inflammation process which can lead to beta cell death and help to preserve them, plus it is only a once a month dose with little or no side effects.

Results from two Phase 3 Trials, demonstrate the effectiveness of this new rapid –acting insulin

Type 2 diabetes patients taking sitagliptin (Januvia) for two years don’t seem to have any extra cardiovascular risk from the agent, according to a pooled analysis of safety data from 12 double-blind, randomized trials.

Results from the DIRECT Program showed that candesartan reduced the incidence of diabetic retinopathy in patients with type 1 diabetes and reduced the regression of retinopathy in those with type 2 diabetes. However, the study did not meet its primary endpoints.

Transition Therapeutics Inc. announced that the first patient has been dosed in a Phase 2 clinical study of gastrin analogue, TT-223.